RU2009123478A - APPLICATION OF BACTERIA CLOSTRIDIUM PERFRINGENS TYPE C FOR PRODUCTION OF VACCINE - Google Patents

APPLICATION OF BACTERIA CLOSTRIDIUM PERFRINGENS TYPE C FOR PRODUCTION OF VACCINE Download PDF

Info

Publication number
RU2009123478A
RU2009123478A RU2009123478/15A RU2009123478A RU2009123478A RU 2009123478 A RU2009123478 A RU 2009123478A RU 2009123478/15 A RU2009123478/15 A RU 2009123478/15A RU 2009123478 A RU2009123478 A RU 2009123478A RU 2009123478 A RU2009123478 A RU 2009123478A
Authority
RU
Russia
Prior art keywords
clostridium perfringens
perfringens type
vaccine
production
infection
Prior art date
Application number
RU2009123478/15A
Other languages
Russian (ru)
Other versions
RU2462263C2 (en
Inventor
Мартен Хендрик ВИТВЛИТ (NL)
Мартен Хендрик ВИТВЛИТ
Йозеф Франсискус Мария СМЕТС (NL)
Йозеф Франсискус Мария СМЕТС
Кит РЕДХЭД (GB)
Кит РЕДХЭД
Original Assignee
Интервет Интернэшнл Б.В. (Nl)
Интервет Интернэшнл Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Интервет Интернэшнл Б.В. (Nl), Интервет Интернэшнл Б.В. filed Critical Интервет Интернэшнл Б.В. (Nl)
Publication of RU2009123478A publication Critical patent/RU2009123478A/en
Application granted granted Critical
Publication of RU2462263C2 publication Critical patent/RU2462263C2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/08Clostridium, e.g. Clostridium tetani

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to the use of a vaccine comprising Clostridium perfringens type C bacterium for protecting swine against Clostridium perfringens type A infection.

Claims (12)

1. Применение бактерии Clostridium perfringens типа C для производства вакцины для защиты зрелых свиней от инфекции Clostridium perfringens типа А.1. The use of the bacterium Clostridium perfringens type C for the production of a vaccine to protect mature pigs from infection with Clostridium perfringens type A. 2. Применение бактерии Clostridium perfringens типа C для производства вакцины для защиты свиноматок от инфекции Clostridium perfringens типа А.2. The use of the bacterium Clostridium perfringens type C for the production of a vaccine to protect sows from infection with Clostridium perfringens type A. 3. Применение бактерии Clostridium perfringens типа C для производства вакцины для свиноматок для защиты поросят от инфекции Clostridium perfringens типа А.3. The use of the bacterium Clostridium perfringens type C for the production of a vaccine for sows to protect piglets from infection with Clostridium perfringens type A. 4. Применение бактерии Clostridium perfringens типа C для производства вакцины для защиты поросят от инфекции Clostridium perfringens типа А.4. The use of the bacterium Clostridium perfringens type C for the production of a vaccine to protect piglets from infection with Clostridium perfringens type A. 5. Применение супернатанта культуры Clostridium perfringens типа C для производства вакцины для защиты зрелых свиней от инфекции Clostridium perfringens типа А.5. Use of Clostridium perfringens type C culture supernatant for vaccine production to protect mature pigs from Clostridium perfringens type A infection. 6. Применение супернатанта культуры Clostridium perfringens типа C для производства вакцины для защиты свиноматок от инфекции Clostridium perfringens типа А.6. The use of the supernatant of the culture of Clostridium perfringens type C for the production of a vaccine to protect sows from infection with Clostridium perfringens type A. 7. Применение супернатанта культуры Clostridium perfringens типа C для производства вакцины для свиноматок для защиты поросят от инфекции Clostridium perfringens типа А.7. The use of the supernatant of Clostridium perfringens type C culture for the production of a vaccine for sows to protect piglets from infection with Clostridium perfringens type A. 8. Применение супернатанта культуры Clostridium perfringens типа C для производства вакцины для защиты поросят от инфекции Clostridium perfringens типа А.8. Use of a Clostridium perfringens type C culture supernatant for the production of a vaccine for protecting piglets from Clostridium perfringens type A infection. 9. Применение по пп.1-8, отличающееся тем, что используют бактерию Clostridium perfringens типа C, которая продуцирует бета-2 токсин.9. The use according to claims 1 to 8, characterized in that they use the bacterium Clostridium perfringens type C, which produces a beta-2 toxin. 10. Применение по пп.1-9, отличающееся тем, что для производства указанной вакцины дополнительно используют один или более антигенов, полученных из патогенных организмов или вирусов свиньи, антитела против данных антигенов или генетическая информация, кодирующая такие антигены.10. The use according to claims 1 to 9, characterized in that for the production of this vaccine, one or more antigens derived from pathogenic organisms or pig viruses, antibodies against these antigens, or genetic information encoding such antigens are additionally used. 11. Применение по п.10, отличающееся тем, что указанный патогенный организм или вирус выбран из группы вируса ложного бешенства, вируса PRRS, вируса свиного гриппа, свиного парвовируса, вируса инфекционного гастроэнтерита, ротавируса, Escherichia coli, Erysipelothrix rhusiopathiae, Bordetella bronchiseptica, Salmonella choleraesuis, Salmonella typhimurium, Haemophilus parasuis, Pasteurella multocida, Streptococcus suis, Mycoplasma hyopneumoniae, Brachyspira hyodysenteriae и Actinobacillus pleuropneumoniae.11. The use according to claim 10, characterized in that the said pathogenic organism or virus is selected from the group of pseudorabies virus, PRRS virus, swine flu virus, swine parvovirus, infectious gastroenteritis virus, rotavirus, Escherichia coli, Erysipelothrix rhusiopathiae, Bordetella bronchiseptica, Salmonella choleraesuis, Salmonella typhimurium, Haemophilus parasuis, Pasteurella multocida, Streptococcus suis, Mycoplasma hyopneumoniae, Brachyspira hyodysenteriae and Actinobacillus pleuropneumoniae. 12. Применение по п.10, отличающееся тем, что указанный патогенный организм свиньи представляет собой Escherichia coli. 12. The use of claim 10, characterized in that the pathogen of the pig is Escherichia coli.
RU2009123478/10A 2006-11-20 2007-11-19 Use of bacterium clostridium perfringens type c for producing vaccine RU2462263C2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86044706P 2006-11-20 2006-11-20
EP06124404 2006-11-20
US60/860,447 2006-11-20
EP06124404.2 2006-11-20

Publications (2)

Publication Number Publication Date
RU2009123478A true RU2009123478A (en) 2010-12-27
RU2462263C2 RU2462263C2 (en) 2012-09-27

Family

ID=38535530

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009123478/10A RU2462263C2 (en) 2006-11-20 2007-11-19 Use of bacterium clostridium perfringens type c for producing vaccine

Country Status (8)

Country Link
CN (1) CN101541343B (en)
AT (1) ATE540692T1 (en)
BR (1) BRPI0718639A2 (en)
DK (1) DK2086578T3 (en)
ES (1) ES2380134T3 (en)
RU (1) RU2462263C2 (en)
TW (1) TWI369991B (en)
UA (1) UA95652C2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102688484B (en) * 2012-06-13 2016-03-30 北京中海生物科技有限公司 A kind of production method of chicken necrotizing enterocolitis (C type) inactivated vaccine
CN107789622A (en) * 2017-10-18 2018-03-13 山东农业大学 A kind of calf enterotoxemia C.perfringens β2The preparation method of toxin toxoid vaccine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2129441C1 (en) * 1997-12-10 1999-04-27 Пирожков Михаил Константинович Mixed vaccine against anaerobic enterotoxemia and escherichiosis in piglets
UA65816A (en) * 2003-05-30 2004-04-15 Vasyl Petrovych Ryzhenko Vaccine velshisan for preventing toxicoinfections caused by clostridium perfringens

Also Published As

Publication number Publication date
RU2462263C2 (en) 2012-09-27
UA95652C2 (en) 2011-08-25
TW200831121A (en) 2008-08-01
BRPI0718639A2 (en) 2013-11-26
DK2086578T3 (en) 2012-05-14
CN101541343B (en) 2012-05-16
ATE540692T1 (en) 2012-01-15
CN101541343A (en) 2009-09-23
ES2380134T3 (en) 2012-05-08
TWI369991B (en) 2012-08-11

Similar Documents

Publication Publication Date Title
RU2010112939A (en) REDUCING RELATED INFECTIONS IN PIGS WITH PCV2 ANTIGEN
HRP20220175T1 (en) Mycoplasma hyopneumoniae vaccine
RU2018117649A (en) IMMUNOGENIC COMPOSITIONS FOR IMMUNIZATION OF PIGS AGAINST TYPE 3 CIRCOVIRUS AND METHODS FOR PRODUCING AND USING THEM
Davies et al. Characterization and comparison of Pasteurella multocida strains associated with porcine pneumonia and atrophic rhinitis
RU2008130927A (en) POLYVALENT IMMUNOGENIC PCV2 COMPOSITIONS AND METHODS FOR PRODUCING SUCH COMPOSITIONS
RU2015115486A (en) ARTERIVIRUS
AR069216A1 (en) COMPOSITION TO CAUSE AN IMMUNE ANTI-MYCOPLASMA HYOPNEUMONIAE AND METHODS RESPONSE
RU2015104165A (en) MUTANT STRAINS MYCOPLASMA HYOPNEUMONIAE
EA200901576A8 (en) VACCINE CONTAINING CONJUGATES OF CAPSULAR POLYSACCHARIDES STREPTOCOCCUS PNEUMONIAE
JP2007320963A5 (en)
RU2014140106A (en) PCV / MYCOPLASMA HYOPNEUMONIAE COMBINED VACCINE
NZ524888A (en) Nucleic acids and proteins from streptococcus groups A & B
JP2015523080A5 (en)
RU2009123478A (en) APPLICATION OF BACTERIA CLOSTRIDIUM PERFRINGENS TYPE C FOR PRODUCTION OF VACCINE
DK1219711T3 (en) Lawsonia Intracellularis vaccine
RU2013128921A (en) VACCINE COMPOSITIONS CONTAINING Bovine VIRAL DIARRHEIA TYPE 1b VIRUS AND METHODS FOR PRODUCING AND USING THEM
Delfani et al. Protection of mice against Staphylococcus aureus infection by a recombinant protein ClfA–IsdB–Hlg as a vaccine candidate
KR20090081389A (en) Use of clostridium perfringens type c bacterium for the manufacture of a vaccine
RU2018137034A (en) PCV2 COMBINED VACCINE AND MYCOPLASMA HYOPNEUMONIAE INFECTION
Sads et al. peer reviewed
WO2014146603A1 (en) Pasteurella multocida toxin recombinant protein and use thereof
Sipos et al. Genotyping of Clostridium perfringens isolated from domestic and exotic ruminants and swine
KR970074928A (en) Attenuated RTX Toxin-producing Live Bacteria from Pasteurella
JP7295223B2 (en) combination vaccine
Confer et al. Evaluation of Pasteurella and Haemophilus vaccines

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20201120